Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer

Amanda FoskettThe Oncology Service, LLC, Leesburg, VA, USA, [email protected]

Christina ManleyThe Oncology Service, LLC, Leesburg, VA, USA, [email protected]

Rebecca NaramoreThe Oncology Service, LLC, Leesburg, VA, USA, [email protected]

Ira K GordonThe Oncology Service, LLC, Leesburg, VA, USA, [email protected]

Bridget M StewartThe Oncology Service, LLC, Leesburg, VA, USA, [email protected]

Chand KhannaThe Oncology Service, LLC, Leesburg, VA, USA, [email protected]Correspondence[email protected]

Pages 97-102 | Published online: 08 Dec 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

GollobJAWilhelmSCarterCKelleySLRole of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathwaySemin Oncol200633439240616890795
PubMed Web of Science ®Google Scholar
LiuLCaoYChenCSorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Cancer Res20066624118511185817178882
PubMed Web of Science ®Google Scholar
ChangFSteelmanLSLeeJTSignal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic interventionLeukemia20031771263129312835716
PubMed Web of Science ®Google Scholar
de CastronevesLANegraoMVde FreitasRMSorafenib for the treatment of progressive metastatic medullary thyroid cancer: efficacy and safety analysisThyroid201626341441926701095
PubMed Web of Science ®Google Scholar
KaneRCFarrellATMadabushiRSorafenib for the treatment of unresectable hepatocellular carcinomaOncologist20091419510019144678
PubMed Web of Science ®Google Scholar
KaneRCFarrellATSaberHSorafenib for the treatment of advanced renal cell carcinomaClin Cancer Res200612247271727817189398
PubMed Web of Science ®Google Scholar
KhannaCLondonCVailDMazckoCHirschfeldSGuiding the optimal translation of new cancer treatments from canine to human cancer patientsClin Cancer Res200915185671567719737961
PubMed Web of Science ®Google Scholar
VailDMMacEwenEGSpontaneously occurring tumors of companion animals as models for human cancerCancer Invest200018878179211107448
PubMed Web of Science ®Google Scholar
LondonCAHannahALZadovoskayaRPhase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignanciesClin Cancer Res2003972755276812855656
PubMed Web of Science ®Google Scholar
PaoloniMKhannaCTranslation of new cancer treatments from pet dogs to humansNat Rev Cancer20088214715618202698
PubMed Web of Science ®Google Scholar
DeckerBParkerHGDhawanDHomologous mutation to human BRAF V600E is common in naturally occurring canine bladder cancer – evidence for a relevant model system and urine-based diagnostic testMol Cancer Res2015136993100225767210
PubMed Web of Science ®Google Scholar
MochizukiHKennedyKShapiroSGBreenMBRAF mutations in canine cancersPLoS One2015106e012953426053201
PubMed Web of Science ®Google Scholar
PatrawalaSPuzanovIVemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitorFuture Oncol20128550952322646766
PubMed Web of Science ®Google Scholar
ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
PubMed Web of Science ®Google Scholar
LeeWJLeeJLChangSECutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibBr J Dermatol200916151045105119558553
PubMed Web of Science ®Google Scholar
WilhelmSChienDSBAY 43-9006: preclinical dataCurr Pharm Des20028252255225712369853
PubMed Web of Science ®Google Scholar
KinironsMTO’MahonyMSDrug metabolism and ageingBr J Clin Pharmacol200457554054415089805
PubMed Web of Science ®Google Scholar
RobertsDJHallRIDrug absorption, distribution, metabolism and excretion considerations in critically ill adultsExpert Opin Drug Metab Toxicol2013991067108423682923
PubMed Web of Science ®Google Scholar
Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1Vet Comp Oncol2011144417446
Google Scholar
SkolnikJMBarrettJSJayaramanBPatelDAdamsonPCShortening the timeline of pediatric phase I trials: the rolling six designJ Clin Oncol200826219019518182661
PubMed Web of Science ®Google Scholar
BurtonJKhannaCThe role of clinical trials in veterinary oncologyVet Clin North Am Small Anim Pract201444597798725174911
PubMed Web of Science ®Google Scholar
ThammDHVailDMVeterinary oncology clinical trials: design and implementationVet J2015205222623225582798
PubMed Web of Science ®Google Scholar
KummarSGutierrezMDoroshowJHMurgoAJDrug development in oncology: classical cytotoxics and molecularly targeted agentsBr J Clin Pharmacol2006621152616842375
PubMed Web of Science ®Google Scholar
DowlatiAMandaSGibbonsJRemickSCPatrickLFuPMulti-institutional phase I trials of anticancer agentsJ Clin Oncol200826121926193118421046
PubMed Web of Science ®Google Scholar
SharylJNassHGThe Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: Workshop SummaryWashington, DCInstitute of Medicine Proceedings2015
Google Scholar
LeBlancAKMazckoCNKhannaCDefining the value of a comparative approach to cancer drug developmentClin Cancer Res20162292133213826712689
PubMed Web of Science ®Google Scholar
WilsonMAZhaoFLetreroRCorrelation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibClin Cancer Res201420123328333724714776
PubMed Web of Science ®Google Scholar
DreicerRLiHSteinMPhase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology GroupCancer2009115184090409519536901
PubMed Web of Science ®Google Scholar
European Medical Agency [webpage on the Internet] Initial Marketing Authorization Study of Nexavar2007 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000690/human_med_000929.jsp&mid=WC0b01ac058001d124Accessed March 4, 2017
Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date